Steven-Johnson Syndrome (SJS) in a Multiple Myeloma patient treated with lenalidomide and low dose dexamethasone regimen: a rare Case Report

2015 ◽  
Vol 3 (3) ◽  
pp. 353-355
Author(s):  
Dr Lohit kumar Kalita ◽  
◽  
Dr Chayanika Kalita ◽  
Dr Pabitra Kamar Gogoi ◽  
Dr Umesh Ch. Sarma ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Case Report ◽  
Rare Case ◽  
Low Dose ◽  
Myeloma Patient ◽  
Multiple Myeloma Patient ◽  
Johnson Syndrome ◽  
Rare Case Report ◽  
Steven Johnson Syndrome

scholarly journals Acremonium-Associated CLABSI in a Multiple Myeloma Patient: Pitfalls in Diagnosis: A Rare Case Report

2012 ◽  
Vol 138 (suppl 2) ◽  
pp. A330-A330
Author(s):  
Rajib Gupta ◽  
Dan Ketterer ◽  
Michael Gelfand ◽  
Vickie Baselski
Keyword(s):  
Multiple Myeloma ◽  
Case Report ◽  
Rare Case ◽  
Myeloma Patient ◽  
Multiple Myeloma Patient ◽  
Rare Case Report

scholarly journals Paracetamol induced Steven-Johnson syndrome: A rare case report

2015 ◽  
Vol 6 (6) ◽  
pp. 278 ◽  
Author(s):  
Rajan Rajput ◽  
Shitalkumar Sagari ◽  
Astha Durgavanshi ◽  
Alpana Kanwar
Keyword(s):  
Case Report ◽  
Rare Case ◽  
Johnson Syndrome ◽  
Rare Case Report ◽  
Steven Johnson Syndrome

A multiple myeloma patient who developed ischemic colitis during lenalidomide treatment: A rare case report

2020 ◽  
Vol 26 (6) ◽  
pp. 1499-1500
Author(s):  
Hikmettullah Batgi ◽  
Mehmet Sinan Dal ◽  
Alparslan Merdin ◽  
Merih Kızıl Çakar ◽  
Tuğçe Nur Yiğenoğlu ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Case Report ◽  
Ischemic Colitis ◽  
Plasma Cells ◽  
Malignant Neoplasm ◽  
Unknown Origin ◽  
Bloody Diarrhea ◽  
Myeloma Patient ◽  
Multiple Myeloma Patient ◽  
Rare Case Report

Introduction Multiple myeloma is a malignant neoplasm of plasma cells. Lenalidomide-dexamethasone treatment is a common treatment regimen used in refractory multiple myeloma. Case report We describe the case of a 58-year-old male multiple myeloma patient with a history of relapse after six months of autologous stem cell transplantation. The patient had nausea and bloody diarrhea developed during lenalidomide treatment. Management and outcome: Computed tomography showed diffuse marked edematous thickness in the wall of colonic, hepatic and splenic flexure, transverse colon, descending colon and sigmoid colon. Colonoscopic observation revealed highly granular, hyperemic and fragile mucosa. Colon biopsy was consistent with ischemic colitis. Lenalidomide treatment was discontinued. One month later, colon findings were detected as normalized through a colonoscopy. Discussion Risk of developing ischemic colitis should be kept in mind in patients receiving lenalidomide which should be discontinued in cases with severe bloody diarrhea of unknown origin.

scholarly journals Abnormal radiological features in a multiple myeloma patient: a case report and radiological review of myelomas

2011 ◽  
Vol 40 (8) ◽  
pp. 513-518 ◽  
Author(s):  
S Ghosh ◽  
P Wadhwa ◽  
A Kumar ◽  
KM Pai ◽  
S Seshadri ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Case Report ◽  
Myeloma Patient ◽  
Multiple Myeloma Patient ◽  
Radiological Features

scholarly journals AB228. SOH21AS200. A rare case of incidental functioning neck paraganglioma in a multiple myeloma patient

2021 ◽  
Vol 5 ◽  
pp. AB228-AB228
Author(s):  
Waris Ali Shah ◽  
Zeeshan Razzaq ◽  
Hamid Mustafa ◽  
Sarah Lungley ◽  
Mohammed Daoud ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Rare Case ◽  
Myeloma Patient ◽  
Multiple Myeloma Patient

scholarly journals Acute Liver Rejection in a Multiple Myeloma Patient Treated with Lenalidomide

2020 ◽  
Vol 2020 ◽  
pp. 1-4
Author(s):  
Iuliana Vaxman ◽  
John Eaton ◽  
Hee Eun Lee ◽  
Morie A. Gertz
Keyword(s):  
Multiple Myeloma ◽  
Mycophenolate Mofetil ◽  
Case Report ◽  
Allograft Rejection ◽  
Acute Cellular Rejection ◽  
Primary Biliary Cholangitis ◽  
Myeloma Patient ◽  
Multiple Myeloma Patient ◽  
First Case ◽  
Cellular Rejection

Herein we present a patient that underwent a liver transplant due to primary biliary cholangitis (PBC) and after 9 years developed multiple myeloma. Following the cessation of mycophenolate mofetil and 2 weeks after lenalidomide treatment was started, the patient experienced acute cellular rejection. The patient recovered after treatment with corticosteroids, resumption of mycophenolate mofetil, and cessation of lenalidomide. Lenalidomide-associated allograft rejection has been reported in other organs. However, this is the first case report of liver rejection induced by lenalidomide.

Sign in / Sign up

Export Citation Format

Share Document